|Videos|March 24, 2021

Studies of Anakinra and Tolebrutinib in MS Paramagnetic Rim Lesions: Jemima Akinsanya, DO

Author(s)Jemima Akinsanya, DO

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

“It's very disheartening as a clinician to not be able to provide more options for [patients with progressive MS]. It’s a huge quality of life hindrance for patients that to be able to provide them with treatments that can help slow the neurodegeneration and not just the acute inflammation would have a huge impact on them. So, I'm excited for that.”

A new phase 2a clinical trial paradigm for multiple sclerosis (MS) is underway, with 2 open-label studies evaluating the effects of anakinra (NCT04025554) and tolebrutinib on 7-Tesla magnetic resonance imaging (MRI) paramagnetic rim lesions (PRL).¹ The studies were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 25-27, by first author Jemima Akinsanya, DO, neuroimmunology clinical fellow, National Institutes of Health (NIH).

Anakinra, approved by the FDA for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease in 2001, is a recombinant human interleukin-1 receptor antagonist.² Tolebrutinib is an investigational, orally available, brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor. Although the study for anakinara is already underway, the study for tolebrutinib is currently enrolling.

NeurologyLive spoke with Akinsanya to learn more about anakinra and tolebrutinib as well as the 2 studies in the clinical program. She also discussed further research she would like to see conducted in progressive MS.

For more coverage of ACTRIMS Forum 2021, click here.

REFERENCES

1. Akinsanya J, Absinta M, Dargah-zade N, et al. Toward the use of paramagnetic rim lesions in proof-of-concept clinical trials for treating chronic inflammation in multiple sclerosis. Presented at ACTRIMS Annual Forum; February 25-27, 2021. Poster P126.
2. Kineret® (anakinra) for injection, for subcutaneous use. FDA label. Updated December 2012. Accessed March 24, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Articles

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
September 13th 2025
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
September 13th 2025
NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD
September 12th 2025
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
September 12th 2025
Expanding the Alzheimer Drug Development Pipeline
September 12th 2025

Latest CME

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

Samuel A. Frank, MD

Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

Carolina Neuromuscular Disease Summit

September 27, 2025

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

Case-based Simulation

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

Jeff Gudin, MD

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

Daniel Claassen, MD, MS; Martha A. Nance, MD

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment Strategies

In-Person + Virtual Event

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment Strategies

October 9, 2025

4th Women in Neurology Conference

In-Person Event

4th Women in Neurology Conference

October 24-26, 2025

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

James F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MD

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Carrie M. Hersh, DO, MSc, FAAN; Anna Shah, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

October 31, 2025

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Trending on NeurologyLive

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

Expanding the Alzheimer Drug Development Pipeline

DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point

Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD

FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency

© 2025 MJH Life Sciences^®

All rights reserved.